ArticleNature aging2021
Author Correction: Experimental and real-world evidence supporting the computational repurposing of bumetanide for APOE4-related Alzheimer's disease.
Open access · bronzeAbstract readPublished Erratum
In one paragraph
Article in Nature aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Sildenafil as a Candidate Drug for Alzheimer's Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons.Journal of Alzheimer's disease : JAD · 2024Article
Corrections and comments
- Erratum for
Authors and funding
26 authors at 3 institutions in 1 country.
Alice TaubesGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
Phil NovaGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
Kelly A ZalocuskyGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
Idit KostiBakar Computational Health Sciences Institute, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-2212-5472
Mesude BicakHasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Misha Y ZilberterGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-7164-8312
Yanxia HaoGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
Seo Yeon YoonGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
Tomiko OskotskyBakar Computational Health Sciences Institute, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-7393-5120
Silvia PinedaBakar Computational Health Sciences Institute, University of California, San Francisco, CA, USA.
Bin ChenBakar Computational Health Sciences Institute, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8858-874X
Emily A Aery JonesGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
Krishna ChoudharyGladstone Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-7966-1527
Brian GroneGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
Maureen E BalestraGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
Fayzan ChaudhryHasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ishan ParanjpeHasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jessica De FreitasHasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nicole KoutsodendrisGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
Nuo ChenGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
Celine WangGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
William ChangGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
Alice AnGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
Benjamin S GlicksbergHasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-4515-8090
Marina SirotaBakar Computational Health Sciences Institute, University of California, San Francisco, CA, USA. marina.sirota@ucsf.edu.ORCID http://orcid.org/0000-0002-7246-6083
Yadong HuangGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA. yadong.huang@gladstone.ucsf.edu.ORCID http://orcid.org/0000-0002-5871-4589
Gladstone Institutes · USIcahn School of Medicine at Mount Sinai · USUniversity of California, San Francisco · US
Funding
ApoE Genotype-Directed Drug Repositioning and Combination Therapy for Alzheimer's DiseaseR01AG057683 · NIA · J. DAVID GLADSTONE INSTITUTES · PI HUANG, YADONG, SIROTA, MARINA · 2017 to 2021
$4.3MSYSTEMATIC DRUG REPURPOSING TARGETING IMMUNE ACTIVATION NETWORKS IN ALZHEIMER'S DISEASE (AD)RF1AG059319 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI EHRLICH, MICHELLE E, GANDY, SAMUEL E. · 2018 to 2018
$4.2MApolipoprotein E4-related Electrophysiological and Metabolic Impairments in Aging and Alzheimer's DiseaseR01AG061150 · NIA · J. DAVID GLADSTONE INSTITUTES · PI ZILBERTER, MISHA YURI · 2019 to 2023
$3.3MRepurpose open data to discover therapeutics for understudied diseasesR01GM134307 · NIGMS · MICHIGAN STATE UNIVERSITY · PI CHEN, BIN · 2019 to 2023
$2.5MApolipoprotein E in Alzheimer's Disease: Molecular MechanismR01AG048017 · NIA · J. DAVID GLADSTONE INSTITUTES · PI HUANG, YADONG · 2015 to 2019
$1.9MIntegrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancersK01ES028047 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, BIN · 2017 to 2020
$682kTargeting glucose metabolism for the treatment of Hepatocellular CarcinomaR21TR001743 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, BIN · 2017 to 2018
$560kDrug Repositioning for ApoE4-Mediated Alzheimer's DiseaseF31AG058439 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TAUBES, ALICE LORRAINE · 2017 to 2017
$36kNCATS NIH HHS R21 TR001743NIA NIH HHS F31 AG058439NIA NIH HHS R01 AG048017NIA NIH HHS R01 AG057683NIA NIH HHS R01 AG061150NIA NIH HHS RF1 AG059319NIEHS NIH HHS K01 ES028047NIGMS NIH HHS R01 GM134307U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS) TR001743U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (NIEHS) ES028047U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) 1F31AG057150U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) 1F31AG058439U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) AG048017U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) AG057683
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.